|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0013216,
umls-concept:C0023972,
umls-concept:C0028945,
umls-concept:C0033223,
umls-concept:C0034897,
umls-concept:C0042679,
umls-concept:C0070167,
umls-concept:C0076080,
umls-concept:C0282460,
umls-concept:C1257890,
umls-concept:C1516985
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-3-21
|
|
pubmed:abstractText |
Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
599-602
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12649108-Adult,
pubmed-meshheading:12649108-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12649108-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12649108-Brain Neoplasms,
pubmed-meshheading:12649108-Dacarbazine,
pubmed-meshheading:12649108-Disease Progression,
pubmed-meshheading:12649108-Drug Resistance, Neoplasm,
pubmed-meshheading:12649108-Female,
pubmed-meshheading:12649108-Humans,
pubmed-meshheading:12649108-Lomustine,
pubmed-meshheading:12649108-Magnetic Resonance Imaging,
pubmed-meshheading:12649108-Male,
pubmed-meshheading:12649108-Middle Aged,
pubmed-meshheading:12649108-Neoplasm Recurrence, Local,
pubmed-meshheading:12649108-Oligodendroglioma,
pubmed-meshheading:12649108-Procarbazine,
pubmed-meshheading:12649108-Treatment Outcome,
pubmed-meshheading:12649108-Vincristine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
|
|
pubmed:affiliation |
Department of Neuro-Oncology, University Hospital Rotterdam/Rotterdam Cancer Center, The Netherlands. bent@neuh.azr.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
